Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2019-06-14 DOI:10.2217/mmt-2019-0002

Robert V Rawson, Teresa Bailey, Andrew J Colebatch, Peter Ferguson

{"title":"Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management.","authors":"Robert V Rawson, Teresa Bailey, Andrew J Colebatch, Peter Ferguson","doi":"10.2217/mmt-2019-0002","DOIUrl":null,"url":null,"abstract":"Hauschild A, Dummer R, Schadendorf D et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant Stage III melanoma. J. Clin. Oncol. 36(35), 3441–3449 (2018) This publication, an update of the COMBI-AD trial, provides the most mature data with extended follow-up in Stage III metastatic melanoma patients treated with immune checkpoint or targeted therapies in the adjuvant setting. The results of this study of Stage III BRAF V600 mutant metastatic melanoma continue to show relapse-free survival (RFS) benefit at 40 months of dabrafenib plus trametinib therapy over placebo with an absolute difference of almost 20% between the arms. The RFS benefit was also confirmed regardless of stage, clinical and pathological subgroups. For the first time, the somewhat controversial, Weibull mixture cure-rate analysis has been used in metastatic melanoma patients and showed estimated cure rates of 54% (treatment arm) versus 37% (placebo arm). Moving forward it will be interesting to compare these results with the results of immunotherapy and combinations therapy trials in the adjuvant and neoadjuvant setting to ascertain the optimal treatment protocol for BRAF-mutant metastatic melanoma patients. – Written by Robert V Rawson","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2019-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2019-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hauschild A, Dummer R, Schadendorf D et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant Stage III melanoma. J. Clin. Oncol. 36(35), 3441–3449 (2018) This publication, an update of the COMBI-AD trial, provides the most mature data with extended follow-up in Stage III metastatic melanoma patients treated with immune checkpoint or targeted therapies in the adjuvant setting. The results of this study of Stage III BRAF V600 mutant metastatic melanoma continue to show relapse-free survival (RFS) benefit at 40 months of dabrafenib plus trametinib therapy over placebo with an absolute difference of almost 20% between the arms. The RFS benefit was also confirmed regardless of stage, clinical and pathological subgroups. For the first time, the somewhat controversial, Weibull mixture cure-rate analysis has been used in metastatic melanoma patients and showed estimated cure rates of 54% (treatment arm) versus 37% (placebo arm). Moving forward it will be interesting to compare these results with the results of immunotherapy and combinations therapy trials in the adjuvant and neoadjuvant setting to ascertain the optimal treatment protocol for BRAF-mutant metastatic melanoma patients. – Written by Robert V Rawson

查看原文本刊更多论文

期刊观察:我们的专家小组重点介绍了与黑色素瘤管理领域相关的各种主题中最重要的研究文章。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.